Multicenter phase II study of the oral MEK inhibitor, CI-1040, in patients with advanced non-small-cell lung, breast, colon, and pancreatic cancer
John Rinehart, Alex A. Adjei, Patricia M. LoRusso, David Waterhouse, J. Randolph Hecht, Ronald B. Natale, Oday Hamid, Mary Varterasian, Peggy Asbury, Eric P. Kaldjian, Stephen Gulyas, David Y. Mitchell, Roman Herrera, Judith S. Sebolt-Leopold, Mark B. Meyer
Dive into the research topics of 'Multicenter phase II study of the oral MEK inhibitor, CI-1040, in patients with advanced non-small-cell lung, breast, colon, and pancreatic cancer'. Together they form a unique fingerprint.